These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6424250)

  • 1. [Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2].
    Lasierra J; Díez MM; Fernández A; Viladés E; Gil M; Velázquez E
    Sangre (Barc); 1983; 28(6):687-95. PubMed ID: 6424250
    [No Abstract]   [Full Text] [Related]  

  • 2. [Activity of ticlopidine and lysine acetylsalicylate in experimental atheromatosis. Effects on the production of PGI2].
    Lasierra J; Viladés E; Fernández A; Díez M; Gil M; Velázquez E
    Arch Farmacol Toxicol; 1985 Aug; 11(2):109-16. PubMed ID: 3936423
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit.
    Bruseghini L; Vilageliu J; Freixes J
    Arzneimittelforschung; 1981; 31(10a):1790-5. PubMed ID: 6797443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plafibride tolerance trial in healthy volunteers.
    Dalmau J; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1845-9. PubMed ID: 7198463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of plafibride, an antiplatelet and hypolipemic agent, on prostacyclin and thromboxane synthesis, 3',5'-cyclic AMP phosphodiesterase activity and serum clearance of a lipid emulsion.
    Vilageliu J; Freixes J; Giráldez A; Bermejo P; Basi N; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1805-7. PubMed ID: 6274363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of plafibride in healthy volunteers.
    Santaniello E; Conti F; Vilageliu J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1850-2. PubMed ID: 7198464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of amino acid derivative of clofibric acid (WKLB-5), and theophylline monoester of nicotinic acid (ME1) on the development of experimental atherosclerosis in rabbits.
    Wójcicki J; Jaworska M; Samochowiec L; Hinek A
    Pol J Pharmacol Pharm; 1986; 38(1):77-84. PubMed ID: 3509959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin.
    Smith MJ; Allen KG; Norman JF; Harris MA; Miller CW
    Prostaglandins Leukot Essent Fatty Acids; 1995 Nov; 53(5):331-40. PubMed ID: 8596771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of plafibride on erythrocyte deformability.
    Vilageliu J; Freixes J; Bruseghini L
    Arzneimittelforschung; 1983; 33(3):401-4. PubMed ID: 6683514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A clofibric acid derivative with hypolipemic and platelet antiaggregant action].
    Dănilă G; Nechifor M; Filip M; Păduraru I; Ifrim C; Grădinariu D; Papa V; Manolescu A; Bădescu A
    Rev Med Chir Soc Med Nat Iasi; 1988; 92(1):127-32. PubMed ID: 3393745
    [No Abstract]   [Full Text] [Related]  

  • 12. Plafibride (ITA 104).
    Arzneimittelforschung; 1981; 31(10a):1781-866. PubMed ID: 7198454
    [No Abstract]   [Full Text] [Related]  

  • 13. Stimulation of anti-aggregatory activity from rat aorta by hypolipidemic drugs.
    Weithmann KU; Granzer E
    Artery; 1980; 8(5):475-81. PubMed ID: 7011266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypolipemic activity of plafibride.
    Bruseghini L; Vilageliu J; Bagaria A
    Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental pharmacological study of moroxybrate, a hypolipidaemic, antithrombotic, antiatheromatous agent.
    Moreau P; Jacotot B; Tillement JP
    J Pharm Pharmacol; 1987 Jan; 39(1):35-8. PubMed ID: 2880981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plafibride: clinical trial of a new platelet antiaggregating agent.
    Olivella J; Vicens B
    Arzneimittelforschung; 1981; 31(10a):1856-8. PubMed ID: 7032532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable effects of the lipid-lowering and platelet antiaggregant Plafibride on the aging process of mice of the C57bl/6J strain.
    Calatayud JM
    Methods Find Exp Clin Pharmacol; 1983 Dec; 5(10):707-14. PubMed ID: 6672489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aspirin on cholesterol-induced platelet activation in rabbits.
    Spławiński J; Corell T; Hasselmann G; Mruk J
    Thromb Res; 1982 Jan 1-15; 25(1-2):155-61. PubMed ID: 7064130
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis and pharmacological evaluation of N'-morpholinomethylurea derivatives with platelet antiaggregant activity.
    Ribalta JM; Artús JJ; Salvador L; Roma E; Vilageliu J; Freixes J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1782-6. PubMed ID: 6797442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.